{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:43:45Z","timestamp":1793411025988,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00228-022-03400-4","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T20:02:45Z","timestamp":1665172965000},"page":"1923-1933","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2814-3049","authenticated-orcid":false,"given":"Carlos","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2061-4718","authenticated-orcid":false,"given":"Ana","family":"Penedones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-8717","authenticated-orcid":false,"given":"Diogo","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-7339","authenticated-orcid":false,"given":"Francisco","family":"Batel Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"3400_CR1","unstructured":"Wollenberg A, Barbarot S, Bieber T et al (2019) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I [published correction appears in J Eur Acad Dermatol Venereol. 33(7):1436]. J Eur Acad Dermatol Venereol 32(5):657\u2013682"},{"key":"3400_CR2","unstructured":"Nemeth V, Evans J (2021) Eczema. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538209\/. Accessed 6 July 2022"},{"key":"3400_CR3","unstructured":"Eichenfield LF, Tom WL, Berger TG et al (2014) Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 71(1):116\u2013132"},{"key":"3400_CR4","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL et al (2021) Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials [published correction appears in Lancet. et al 2021 Jun 5;397(10290):2150] Lancet 397(10290):2151\u20132168","DOI":"10.1016\/S0140-6736(21)00588-2"},{"issue":"1","key":"3400_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW et al (2022) Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol 86(1):104\u2013112","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3400_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L et al (2020) Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 183(2):242\u2013255","journal-title":"Br J Dermatol"},{"key":"3400_CR7","unstructured":"European Medicines Agency. Human medicine European public assessment report (EPAR): Cibinqo. Direct healthcare professional communications (DHPC). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cibinqo. Accessed 6 July 2022"},{"key":"3400_CR8","unstructured":"European Medicines Agency. Human medicine European public assessment report (EPAR): Olumiant. Direct healthcare professional communications (DHPC). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant. Accessed 6 July 2022"},{"issue":"10","key":"3400_CR9","first-page":"1755","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S et al (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatol (United Kingdom) 58(10):1755\u20131766","journal-title":"Rheumatol (United Kingdom)"},{"key":"3400_CR10","unstructured":"European Medicines Agency. Human medicine European public assessment report (EPAR): Xeljanz. Direct healthcare professional communications (DHPC). https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/xeljanz-tofacitinib-increased-risk-major-adverse-cardiovascular-events-malignancies-use-tofacitinib. Accessed 6 July 2022"},{"key":"3400_CR11","unstructured":"US Food and Drug Administration. Advisory Committee Meeting: Arthritis Advisory Committee Meeting. NDA 207924 Baricitinib Janus Kinase (JAK) inhibitor for RA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/207924Orig1s000MedR.pdf. Accessed 6 July 2022"},{"key":"3400_CR12","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research Application. Number 207924Orig1s000. Summary Review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/207924Orig1s000ClinPharmR.pdf. Accessed 6 July\u00a02022"},{"issue":"5","key":"3400_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","volume":"158","author":"AM Drucker","year":"2022","unstructured":"Drucker AM, Morra DE, Prieto-Merino D et al (2022) Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol 158(5):523\u2013532","journal-title":"JAMA Dermatol"},{"key":"3400_CR14","unstructured":"Li C, Sun X, Zhao K et al (2021) Efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis published online ahead of print, 2021 Aug 27. Dermatology 1\u201311"},{"key":"3400_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.682547","volume":"8","author":"M Le","year":"2021","unstructured":"Le M, Berman-Rosa M, Ghazawi FM et al (2021) Systematic review on the efficacy and safety of oral Janus kinase inhibitors for the treatment of atopic dermatitis. Front Med (Lausanne) 8:682547","journal-title":"Front Med (Lausanne)"},{"key":"3400_CR16","unstructured":"University of York, Centre for Reviews and Dissemination. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf. Accessed 6 July 2022"},{"issue":"11","key":"3400_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"issue":"92","key":"3400_CR18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","volume":"60","author":"JM Hanifin","year":"1980","unstructured":"Hanifin JM, Rajka G (1980) Diagnostic features of atopic dermatitis. Acta Derm Venereol 60(92):44\u201347","journal-title":"Acta Derm Venereol"},{"key":"3400_CR19","unstructured":"Eichenfield LF, Tom WL, Chamlin SL et al (2014) Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 70(2): 338\u201351"},{"issue":"10","key":"3400_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/1346-8138.13392","volume":"43","author":"H Saeki","year":"2016","unstructured":"Saeki H, Nakahara T, Tanaka A et al (2016) Clinical practice guidelines for the management of atopic dermatitis 2016. J Dermatol 43(10):1117\u20131145","journal-title":"J Dermatol"},{"key":"3400_CR21","first-page":"1","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:1\u20138","journal-title":"BMJ"},{"issue":"4","key":"3400_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1008929526011","volume":"10","author":"DJ Lunn","year":"2000","unstructured":"Lunn DJ, Thomas A, Best N et al (2000) WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 10(4):325\u2013337","journal-title":"Stat Comput"},{"key":"3400_CR23","unstructured":"The Core Model (2018) In: Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ, editors. Network meta-analysis for decision-making. Hoboken, NJ: John Wiley & Sons, Ltd, pp 19\u201357"},{"key":"3400_CR24","doi-asserted-by":"crossref","unstructured":"Model Fit, Model comparison and outlier detection (2018) In: Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ, editors. Network meta-analysis for decision-making. Hoboken, NJ: John Wiley & Sons, Ltd, pp 59\u201391","DOI":"10.1002\/9781118951651.ch3"},{"issue":"5","key":"3400_CR25","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s10067-018-04406-z","volume":"38","author":"V Venerito","year":"2019","unstructured":"Venerito V, Lopalco G, Cacciapaglia F, Fornaro M, Iannone F (2019) A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis. Clin Rheumatol 38(5):1309\u20131317","journal-title":"Clin Rheumatol"},{"issue":"12","key":"3400_CR26","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ejca.2015.04.027","volume":"51","author":"M Yan","year":"2015","unstructured":"Yan M, Kumachev A, Siu LL, Chan KK (2015) Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis. Eur J Cancer 51(12):1570\u20131579","journal-title":"Eur J Cancer"},{"key":"3400_CR27","unstructured":"Dias S, Welton NJ, Sutton AJ et al (2022) NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: National Institute for Health and Care Excellence (NICE). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310366\/. Accessed 6 July\u00a02022"},{"key":"3400_CR28","doi-asserted-by":"crossref","unstructured":"Adverse events and other sparse outcome data (2018) In: Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ, editors. Network meta-analysis for decision-making. Hoboken, NJ: John Wiley & Sons, Ltd. 179\u2013187","DOI":"10.1002\/9781118951651.ch6"},{"issue":"3","key":"3400_CR29","volume":"2","author":"L Bao","year":"2013","unstructured":"Bao L, Zhang H, Chan LS (2013) The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT 2(3):e24137","journal-title":"JAKSTAT"},{"key":"3400_CR30","doi-asserted-by":"publisher","unstructured":"Wood H, Chandler A, Nezamololama N, Papp K, Gooderham MJ (2021) Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis published online ahead of print, 2021 Aug 22. Int J Dermatol. https:\/\/doi.org\/10.1111\/ijd.15853","DOI":"10.1111\/ijd.15853"},{"key":"3400_CR31","doi-asserted-by":"crossref","unstructured":"Sher J, Hahn K, Paul M et al (2013) Incidence and severity of pediatric allergic\/immunologic adverse drug reactions in a tertiary care center. J Allergy Clin Immunol 131(2):AB175","DOI":"10.1016\/j.jaci.2012.12.1287"},{"issue":"4","key":"3400_CR32","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS (2021) JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol 148(4):927\u2013940","journal-title":"J Allergy Clin Immunol"},{"key":"3400_CR33","doi-asserted-by":"crossref","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T (2020) Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study [published correction appears in. 2021 Oct 85(4):1069 J Am Acad Dermatol 82:(4)823\u2013831","DOI":"10.1016\/j.jaad.2019.12.015"},{"issue":"4","key":"3400_CR34","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L et al (2021) Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol 85(4):863\u2013872","journal-title":"J Am Acad Dermatol"},{"key":"3400_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1786","volume":"361","author":"RJ Silverwood","year":"2018","unstructured":"Silverwood RJ, Forbes HJ, Abuabara K et al (2018) Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ 361:k1786","journal-title":"BMJ"},{"issue":"5","key":"3400_CR36","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.jaci.2018.11.030","volume":"143","author":"A Ascott","year":"2019","unstructured":"Ascott A, Mulick A, Yu AM et al (2019) Atopic eczema and major cardiovascular outcomes: a systematic review and meta-analysis of population-based studies. J Allergy Clin Immunol 143(5):1821\u20131829","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"3400_CR37","doi-asserted-by":"publisher","first-page":"775","DOI":"10.5551\/jat.46383","volume":"26","author":"Nishida Y, Kubota Y, Iso H, Tamakoshi A; JACC Study Group","year":"2019","unstructured":"Nishida Y, Kubota Y, Iso H, Tamakoshi A; JACC Study Group (2019) Self-reported eczema in relation with mortality from cardiovascular disease in Japanese: the Japan Collaborative Cohort Study. J Atheroscler Thromb 26(9):775\u2013782","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"3400_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","volume":"126","author":"V Wang","year":"2021","unstructured":"Wang V, Boguniewicz J, Boguniewicz M, Ong PY (2021) The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol 126(1):3\u201312","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"3400_CR39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.anai.2018.12.001","volume":"122","author":"V Wang","year":"2019","unstructured":"Wang V, Keefer M, Ong PY (2019) Antibiotic choice and methicillin-resistant Staphylococcus aureus rate in children hospitalized for atopic dermatitis. Ann Allergy Asthma Immunol 122(3):314\u2013317","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"3400_CR40","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jid.2017.01.030","volume":"137","author":"SM Langan","year":"2017","unstructured":"Langan SM, Abuabara K, Henrickson SE, Hoffstad O, Margolis DJ (2017) Increased risk of cutaneous and systemic infections in atopic dermatitis-a cohort study. J Invest Dermatol 137(6):1375\u20131377","journal-title":"J Invest Dermatol"},{"issue":"4","key":"3400_CR41","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ahj.2013.07.010","volume":"166","author":"CS Crowson","year":"2013","unstructured":"Crowson CS, Liao KP, Davis JM 3rd et al (2013) Rheumatoid arthritis and cardiovascular disease. Am Heart J 166(4):622-628.e1","journal-title":"Am Heart J"},{"issue":"9","key":"3400_CR42","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","volume":"71","author":"JA Avina-Zubieta","year":"2012","unstructured":"Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71(9):1524\u20131529","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3400_CR43","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1136\/ard.2010.143396","volume":"70","author":"J Lindhardsen","year":"2011","unstructured":"Lindhardsen J, Ahlehoff O, Gislason GH et al (2011) The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 70(6):929\u2013934","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3400_CR44","first-page":"505","volume":"59","author":"SA Provan","year":"2020","unstructured":"Provan SA, Lillegraven S, Sexton J et al (2020) Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study. Rheumatology (Oxford) 59(3):505\u2013512","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3400_CR45","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","volume":"2","author":"M Genovese","year":"2020","unstructured":"Genovese M, Smolen J, Takeuchi T et al (2020) Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol 2(6):e347\u2013e357","journal-title":"Lancet Rheumatol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03400-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T16:20:04Z","timestamp":1701188404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03400-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3400"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03400-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"6 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}